SUBJECT_ID	PARENT_ID	TYPE	TIMEPOINT	AGE	RACE	ER_STATUS	POST_TRE_RESPONSE	PGR_STATUS	PTNM_T	PTNM_N	BMN_GRADE	ER_LEVEL	HER2_STATUS	HER2_IHC	HER2_FISH	HIST_TUMOR_TYPE	TREATMENT
M106		PATIENT		57	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	100	NEGATIVE	1	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M107		PATIENT		47	AFRICAN-AMERICAN	POSITIVE	RD	NEGATIVE	T3	N1	3	90	NEGATIVE	2	1.27	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M108		PATIENT		39	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N0	3	90	POSITIVE	3	4.8	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M111		PATIENT		50	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T3	N1	3	0	NEGATIVE	1	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M113		PATIENT		75	AFRICAN-AMERICAN	NEGATIVE	RD	NEGATIVE	T2	N0	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M116		PATIENT		49	HISPANIC	NEGATIVE	PCR	NEGATIVE	T4	N2	3	0	POSITIVE		10.7	1||17	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M117		PATIENT		34	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N1	2	75	NEGATIVE	2	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M120		PATIENT		52	ASIAN	NEGATIVE	RD	POSITIVE	T2	N0	3	0	NEGATIVE	0	1.1	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M121		PATIENT		65	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T1	N0	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M123		PATIENT		52	CAUCASIAN	POSITIVE	PCR	NEGATIVE	T3	N1	1	95	NEGATIVE	1	1.95	2||1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M126		PATIENT		59	CAUCASIAN	NEGATIVE	RD	POSITIVE	T4	N0	3	0	NEGATIVE	2	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M128		PATIENT		67	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	NEGATIVE	1	1.95	2||1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M129		PATIENT		61	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N0	2	0	NEGATIVE	2	1.11	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M130		PATIENT		66	ASIAN	NEGATIVE	RD	POSITIVE	T2	N1	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M133		PATIENT		38	HISPANIC	NEGATIVE	RD	NEGATIVE	T2	N0	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M135		PATIENT		51	CAUCASIAN	POSITIVE	RD	NEGATIVE	T3	N0	3	95	POSITIVE	2	6.1	2||1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M136		PATIENT		38	HISPANIC	NEGATIVE	PCR	POSITIVE	T1	N0	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M139		PATIENT		51	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	85	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M141		PATIENT		70	HISPANIC	POSITIVE	PCR	NEGATIVE	T0	N1	2	50	POSITIVE		10.56	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M145		PATIENT		45	HISPANIC	POSITIVE	RD	POSITIVE	T3	N2	2	80	POSITIVE	3	3.49	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M146		PATIENT		40	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T1	N0	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M153		PATIENT		61	CAUCASIAN	NEGATIVE	PCR	POSITIVE	T1	N1	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M154		PATIENT		29	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	NEGATIVE	0	1.95	1||17	Taxol
M155		PATIENT		62	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	3	80	NEGATIVE	0	1.2	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M156		PATIENT		67	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N2	2	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M157		PATIENT		57	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	NEGATIVE	2	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M158		PATIENT		38	ASIAN	POSITIVE	RD	POSITIVE	T2	N2	2	50	NEGATIVE	1	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M159		PATIENT		59	ASIAN	NEGATIVE	PCR	NEGATIVE	T2	N0	3	0	POSITIVE		5.5	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M161		PATIENT		44	CAUCASIAN	NEGATIVE	PCR	POSITIVE	T2	N1	3	0	POSITIVE	3	6	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M165		PATIENT		50	AFRICAN-AMERICAN	POSITIVE	RD	NEGATIVE	T2	N1	2	90	NEGATIVE	0	1.95	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M176		PATIENT		77	MIXED	POSITIVE	RD	NEGATIVE	T4	N1	2	10	POSITIVE	2	3.6	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M177		PATIENT		42	AFRICAN-AMERICAN	POSITIVE	PCR	NEGATIVE	T3	N0	3	80	NEGATIVE	1	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M179		PATIENT		54	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	5	POSITIVE	2	4.8	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M180		PATIENT		44	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	1	1.95	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M181		PATIENT		75	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N1	2	20	NEGATIVE	0	1.95	2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M182		PATIENT		46	HISPANIC	POSITIVE	RD	POSITIVE	T1	N0	2	100	NEGATIVE	0	1.95	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M186		PATIENT		54	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N0	3	0	POSITIVE	3	7	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M188		PATIENT		68	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T2	N1	1	100	NEGATIVE		1.21	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M189		PATIENT		47	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	3	80	NEGATIVE	1	1.12	18	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M195		PATIENT		42	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	80	NEGATIVE		1.17	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M196		PATIENT		69	ASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	90	NEGATIVE	0	1.95	18||1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M199		PATIENT		46	AFRICAN-AMERICAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	POSITIVE	3	1.09	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M201		PATIENT		75	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	90	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M205		PATIENT		35	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T1	N1	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M206		PATIENT		48	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N0	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M211		PATIENT		52	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T3	N2	3	0	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M212		PATIENT		42	ASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	POSITIVE		20	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M214		PATIENT		54	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	80	NEGATIVE		1.15	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M215		PATIENT		44	AFRICAN-AMERICAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	2	1.7	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M216		PATIENT		59	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	95	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M217		PATIENT		52	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	50	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M220		PATIENT		38	CAUCASIAN	POSITIVE	RD	NEGATIVE	T3	N1	3	70	NEGATIVE	0	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M226		PATIENT		31	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	40	NEGATIVE	1	0.98	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M227		PATIENT		38	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N1	3	30	NEGATIVE	1	1.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M228		PATIENT		53	AFRICAN-AMERICAN	POSITIVE	RD	NEGATIVE	T4	N1	2	80	NEGATIVE	0	0.81	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M230		PATIENT		58	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	POSITIVE	3	4.26	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M230R1		PATIENT		58	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	POSITIVE	3	4.26	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M231		PATIENT		52	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	95	NEGATIVE	0	0.98	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M231R1		PATIENT		52	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	95	NEGATIVE	0	0.98	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M232		PATIENT		49	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T1	N1	3	1	POSITIVE	3	8	1	
M233		PATIENT		60	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N3	3	0	NEGATIVE	0	1	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M233R1		PATIENT		60	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N3	3	0	NEGATIVE	0	1	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M234		PATIENT		58	CAUCASIAN	POSITIVE	RD	NEGATIVE	T3	N1	2	85	NEGATIVE	1	1.02	1||2||16	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M235		PATIENT		53	AFRICAN-AMERICAN	NEGATIVE	RD	NEGATIVE	T3	N1	3	0	POSITIVE	3	2.98	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M235R1		PATIENT		53	AFRICAN-AMERICAN	NEGATIVE	RD	NEGATIVE	T3	N1	3	0	POSITIVE	3	2.98	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M236		PATIENT		53	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	90	NEGATIVE	1	1	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M236R1		PATIENT		53	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	90	NEGATIVE	1	1	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M237		PATIENT		51	HISPANIC	POSITIVE	RD	NEGATIVE	T2	N3	3	50	POSITIVE	3	9.52	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M237R1		PATIENT		51	HISPANIC	POSITIVE	RD	NEGATIVE	T2	N3	3	50	POSITIVE	3	9.52	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M238		PATIENT		56	ASIAN	POSITIVE	PCR	POSITIVE	T2	N0	2	91	POSITIVE	3	3.64	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M238R1		PATIENT		56	ASIAN	POSITIVE	PCR	POSITIVE	T2	N0	2	91	POSITIVE	3	3.64	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M239		PATIENT		55	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N0	3	0	POSITIVE	3	7.55	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M239R1		PATIENT		55	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N0	3	0	POSITIVE	3	7.55	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M245		PATIENT		52	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N3	3	90	POSITIVE	2	4.5	1||15	Taxol||Herceptin||5-fluorouracil||Doxorubicin||Cyclophosphamide
M245R1		PATIENT		52	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N3	3	90	POSITIVE	2	4.5	1||15	Taxol||Herceptin||5-fluorouracil||Doxorubicin||Cyclophosphamide
M246		PATIENT		42	HISPANIC	POSITIVE	RD	NEGATIVE	T1	N1	3	70	NEGATIVE	0	1.05	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M246R1		PATIENT		42	HISPANIC	POSITIVE	RD	NEGATIVE	T1	N1	3	70	NEGATIVE	0	1.05	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M247		PATIENT		54	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N0	2	80	NEGATIVE	0	1.02	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M247R1		PATIENT		54	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N0	2	80	NEGATIVE	0	1.02	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M251		PATIENT		79	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N1	3	100	POSITIVE	3	5.23	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M255		PATIENT		48	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N3	2	0	NEGATIVE	1	0.98	1||2||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M256		PATIENT		79	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N3	3	90	NEGATIVE	2	1.19	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M256R1		PATIENT		79	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N3	3	90	NEGATIVE	2	1.19	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M257		PATIENT		73	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	POSITIVE	3	7.81	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M257R1		PATIENT		73	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	POSITIVE	3	7.81	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M258		PATIENT		39	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N1	3	0	POSITIVE	3	4.8	1	Taxol||Herceptin||5-fluorouracil||Doxorubicin||Cyclophosphamide
M258R1		PATIENT		39	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N1	3	0	POSITIVE	3	4.8	1	Taxol||Herceptin||5-fluorouracil||Doxorubicin||Cyclophosphamide
M259		PATIENT		39	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	3	20	POSITIVE	3	1.2	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M260		PATIENT		50	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N1	3	50	NEGATIVE	0		1||2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M261		PATIENT		56	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	85	NEGATIVE		1.01	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M263		PATIENT		72	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	1		NEGATIVE		1.06	2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M264		PATIENT		62	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T4	N3	3	95	POSITIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M264R1		PATIENT		62	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T4	N3	3	95	POSITIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M266		PATIENT		45	ASIAN	POSITIVE	RD	NEGATIVE	T2	N3	3	80	NEGATIVE	1	0.7	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M266R1		PATIENT		45	ASIAN	POSITIVE	RD	NEGATIVE	T2	N3	3	80	NEGATIVE	1	0.7	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M270		PATIENT		67	CAUCASIAN	POSITIVE	RD	NEGATIVE	T4	N0	3	90	NEGATIVE	0	0.69	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M270R1		PATIENT		67	CAUCASIAN	POSITIVE	RD	NEGATIVE	T4	N0	3	90	NEGATIVE	0	0.69	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M280		PATIENT		71	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N3	3	95	NEGATIVE	2	1.07	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M280R1		PATIENT		71	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N3	3	95	NEGATIVE	2	1.07	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M281		PATIENT		45	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	100	NEGATIVE	0	1.02	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M282		PATIENT		44	CAUCASIAN	POSITIVE	RD	NEGATIVE	T1	N1	2	90	NEGATIVE	0		IC||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M283		PATIENT		46	CAUCASIAN	POSITIVE	RD	NEGATIVE	T4	N1	3	95	NEGATIVE		0.71	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M286		PATIENT		51	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T3	N1	3	0	POSITIVE	2	2.71	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M286R1		PATIENT		51	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T3	N1	3	0	POSITIVE	2	2.71	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M287		PATIENT		55	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	POSITIVE		9.01	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M294		PATIENT		53	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T1	N1	2	0	POSITIVE		8.9	1	
M295		PATIENT		48	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	2	NEGATIVE	0	1.55	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M297		PATIENT		65	AFRICAN-AMERICAN	POSITIVE	RD	NEGATIVE	T4	N2	2	90	NEGATIVE		1.39	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M301		PATIENT		46	AFRICAN-AMERICAN	NEGATIVE	PCR	NEGATIVE	T3	N1	3	5	NEGATIVE	0	0.986	1||20	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M302		PATIENT		50	MIXED	NEGATIVE	RD	POSITIVE	T2	N3	3	0	POSITIVE		9.09	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M302R1		PATIENT		50	MIXED	NEGATIVE	RD	POSITIVE	T2	N3	3	0	POSITIVE		9.09	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M304		PATIENT		46	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	NEGATIVE		1.1	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M309		PATIENT		62	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	POSITIVE		8.77	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M310		PATIENT		51	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	2	0	NEGATIVE		1.07	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M314		PATIENT		46	AFRICAN-AMERICAN	NEGATIVE	RD	NEGATIVE	T3	N3	3	0	NEGATIVE		1.06	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M315		PATIENT		36	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2		NEGATIVE		1.02	1||2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M316		PATIENT		45	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T4	N3	3	0	POSITIVE	3	4.59	1||15	Taxol||Herceptin||
M316R1		PATIENT		45	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T4	N3	3	0	POSITIVE	3	4.59	1||15	Taxol||Herceptin||5-fluorouracil||Epirubicin||Cyclophosphamide
M319		PATIENT		26	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	95	NEGATIVE		0.92	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M322		PATIENT		65	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	3	50	POSITIVE		2.5	1||2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M322R1		PATIENT		65	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	3	50	POSITIVE		2.5	1||2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M323		PATIENT		40	HISPANIC	POSITIVE	RD	POSITIVE	T1	N2	3	90	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M330		PATIENT		35	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N3	2	10	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M330R1		PATIENT		35	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N3	2	10	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M331		PATIENT		71	HISPANIC	NEGATIVE	PCR	NEGATIVE	T1	N1	2	0	POSITIVE	3	9.26	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M331R1		PATIENT		71	HISPANIC	NEGATIVE	PCR	NEGATIVE	T1	N1	2	0	POSITIVE	3	9.26	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M332		PATIENT		42	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N1	3	50	NEGATIVE		1.09	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M333		PATIENT		67	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	3	100	NEGATIVE		1.88	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M333R1		PATIENT		67	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	3	100	NEGATIVE		1.88	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M334		PATIENT		63	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T1	N1	3	0	NEGATIVE	1	1.05	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M339		PATIENT		44	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	3	0	NEGATIVE	0	0.99	1||19	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M340		PATIENT		54	HISPANIC	POSITIVE	RD	NEGATIVE	T4	N1	2	100	NEGATIVE		0.88	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M341		PATIENT		41	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	80	NEGATIVE		0.96	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M343		PATIENT		50	ASIAN	POSITIVE	RD	POSITIVE	T2	N3	2	90	NEGATIVE	2	0.86	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M345		PATIENT		39	AFRICAN-AMERICAN	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	NEGATIVE	0	1.06	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M353		PATIENT		51	HISPANIC	POSITIVE	PCR	NEGATIVE	T3	N2	3	100	NEGATIVE		1.19	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M355		PATIENT		59	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N2	1	90	NEGATIVE		1.11	2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M356		PATIENT		55	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	100	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M357		PATIENT		52	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	100	NEGATIVE		0.95	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M360		PATIENT		56	CAUCASIAN	POSITIVE	RD	POSITIVE	T0	N3	3	90	NEGATIVE		1.22	2	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M363		PATIENT		58	ASIAN	POSITIVE	RD	POSITIVE	T3	N0	3	100	NEGATIVE		0.78	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M365		PATIENT		42	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	1	90	NEGATIVE		1.02	2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M367		PATIENT		62	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T4	N1	3	0	NEGATIVE			1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M371		PATIENT		51	HISPANIC	NEGATIVE	PCR	NEGATIVE	T4	N3	3	0	POSITIVE	3	6.25	1	Taxol||Herceptin||5-fluorouracil||Doxorubicin||Cyclophosphamide
M371R1		PATIENT		51	HISPANIC	NEGATIVE	PCR	NEGATIVE	T4	N3	3	0	POSITIVE	3	6.25	1	Taxol||Herceptin||5-fluorouracil||Doxorubicin||Cyclophosphamide
M373		PATIENT		46	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	2	0	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M375		PATIENT		64	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	3	0	NEGATIVE	1	0.99	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M375R1		PATIENT		64	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	3	0	NEGATIVE	1	0.99	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M382		PATIENT		55	AFRICAN-AMERICAN	NEGATIVE	PCR	NEGATIVE	T2	N3	3	0	POSITIVE		10.36	1	
M384		PATIENT		60	HISPANIC	POSITIVE	RD	POSITIVE	T3	N0	2	50	NEGATIVE		1.05	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M385		PATIENT		65	CAUCASIAN	POSITIVE	RD	POSITIVE	T1	N1	2	100	POSITIVE	2	2.67	1	
M386		PATIENT		42	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	2	100	NEGATIVE		1.67	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M386R1		PATIENT		42	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	2	100	NEGATIVE		1.67	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M387		PATIENT		28	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N0	3	90	POSITIVE	3	5.75	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M387R1		PATIENT		28	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N0	3	90	POSITIVE	3	5.75	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M396		PATIENT		35	HISPANIC	POSITIVE	RD	NEGATIVE	T2	N2	1	90	NEGATIVE	1	1.11	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M399		PATIENT		40	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	90	NEGATIVE		1	1||15	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M402		PATIENT		38	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T4	N1	3	5	NEGATIVE		0.68	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M402R1		PATIENT		38	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T4	N1	3	5	NEGATIVE		0.68	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M411		PATIENT		44	ASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	70	NEGATIVE	1	1	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M417		PATIENT		63	HISPANIC	POSITIVE	RD	POSITIVE	T2	N1	2	100	NEGATIVE		1.11	2	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M421		PATIENT		48	CAUCASIAN	POSITIVE	RD	NEGATIVE	T3	N1	2	70	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M423		PATIENT		68	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T0	N3	2	10	NEGATIVE	0		1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M425		PATIENT		60	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N1	2	0	NEGATIVE		1.04	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M430		PATIENT		52	AFRICAN-AMERICAN	NEGATIVE	RD	NEGATIVE	T3	N1	3	0	NEGATIVE		1.01	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M431		PATIENT		50	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	25	NEGATIVE	1	0.94	1||2	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M433		PATIENT		47	HISPANIC	POSITIVE	RD	POSITIVE	T2	N0	3	70	NEGATIVE	0		1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M434		PATIENT		50	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	40	NEGATIVE	1	1.07	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M442		PATIENT		41	CAUCASIAN	POSITIVE	PCR	POSITIVE	T3	N1	3	80	NEGATIVE	0	1.08	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M443		PATIENT		46	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T3	N2	3	0	POSITIVE	3	6	1	
M447		PATIENT		44	AFRICAN-AMERICAN	POSITIVE	RD	NEGATIVE	T2	N0	2	95	NEGATIVE		1.63	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M463		PATIENT		60	HISPANIC	POSITIVE	RD	NEGATIVE	T4	N1	3	100	NEGATIVE		0.71	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M469		PATIENT		57	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N3	2	90	NEGATIVE		1.08	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M482		PATIENT		47	HISPANIC	POSITIVE	RD	NEGATIVE	T2	N3	3	80	POSITIVE		9.43	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M484		PATIENT		55	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	2		NEGATIVE		0.94	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M485		PATIENT		50	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T4	N2	3	1	NEGATIVE		1.04	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M486		PATIENT		44	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	3	80	NEGATIVE			1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M497		PATIENT		62	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N3	3	20	NEGATIVE	1	1.36	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M502		PATIENT		50	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N0	2	0	NEGATIVE		1.6	1||2	5-fluorouracil||Epirubicin||Cyclophosphamide||Taxol
M503		PATIENT		38	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T1	N0	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M506		PATIENT		46	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	3	95	NEGATIVE		1.04	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M507		PATIENT		66	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	95	NEGATIVE	1	0.91	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M513		PATIENT		59	AFRICAN-AMERICAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	1	0.96	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M523		PATIENT		47	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	100	NEGATIVE		1	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M524		PATIENT		31	HISPANIC	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M525		PATIENT		46	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	3	40	NEGATIVE	1	0.83	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M531		PATIENT		53	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N3	3	0	NEGATIVE	1	1.2	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M534		PATIENT		46	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N3	2	100	NEGATIVE		1.14	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M545		PATIENT		58	AFRICAN-AMERICAN	NEGATIVE	RD	NEGATIVE	T2	N1	3	0	NEGATIVE	2	1.08	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M549		PATIENT		40	HISPANIC	POSITIVE	RD	POSITIVE	T2	N1	2	100	NEGATIVE		1.17	1||2	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M556		PATIENT		47	CAUCASIAN	POSITIVE	RD	POSITIVE	T1	N1	2	90	NEGATIVE	1	1.06	1||2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide||Hormone Therapy
M557		PATIENT		57	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N3	3	1	NEGATIVE		1.17	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M558		PATIENT		62	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N3	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M559		PATIENT		55	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	70	NEGATIVE		1.14	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M564		PATIENT		68	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M566		PATIENT		39	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N3	2	90	NEGATIVE		1.22	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M571		PATIENT		32	AFRICAN-AMERICAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	0		1	5-fluorouracil||Doxorubicin||Cyclophosphamide||Taxol
M576		PATIENT		70	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	3	0	POSITIVE		7.25	1	
M578		PATIENT		45	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T4	N1	3	100	NEGATIVE	2	1.55	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M583		PATIENT		51	CAUCASIAN	NEGATIVE	RD	POSITIVE	T2	N3	2	0	NEGATIVE	0	0.97	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M599		PATIENT		50	CAUCASIAN	POSITIVE	RD	POSITIVE	T1	N1	1	80	NEGATIVE	2	1.47	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M607		PATIENT		67	CAUCASIAN	POSITIVE	RD	NEGATIVE	T1	N1	2	90	NEGATIVE		1.21	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M610		PATIENT		47	HISPANIC	POSITIVE	RD	POSITIVE	T3	N2	2	80	NEGATIVE	1	1.32	1||LDC	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M612		PATIENT		40	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N2	3	1	NEGATIVE		1.23	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M617		PATIENT		50	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	3	0	NEGATIVE		1.2	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M619		PATIENT		52	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	NEGATIVE		1.05	1	5-fluorouracil||Doxorubicin||Cyclophosphamide||Taxol||XRT||Xeloda
M626		PATIENT		45	HISPANIC	NEGATIVE	RD	NEGATIVE	T2	N1	3		POSITIVE	3	1.1	1	
M642		PATIENT		45	HISPANIC	POSITIVE	RD	POSITIVE	T4	N2	2	95	NEGATIVE		1.09	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M643		PATIENT		41	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	NEGATIVE	1	1.08	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M647		PATIENT		65	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T3	N1	3	0	NEGATIVE	2	0.93	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M651		PATIENT		61	CAUCASIAN	POSITIVE	PCR	POSITIVE	T2	N1	3	90	NEGATIVE		1.3	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M652		PATIENT		66	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	20	NEGATIVE	0		1||2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M657		PATIENT		48	HISPANIC	NEGATIVE	RD	POSITIVE	T1	N0	2	0	NEGATIVE	1	0.96	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M658		PATIENT		61	HISPANIC	NEGATIVE	PCR	NEGATIVE	T3	N3	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M659		PATIENT		51	ASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	3	0	NEGATIVE	1	1.05	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M661		PATIENT		49	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	2	0.79	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M662		PATIENT		46	ASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	90	NEGATIVE	0	0.89	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M665		PATIENT		57	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M666		PATIENT		58	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	100	NEGATIVE		0.91	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M668		PATIENT		50	ASIAN	POSITIVE	RD	POSITIVE	T3	N2	3	80	NEGATIVE		2	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M669		PATIENT		47	ASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	90	NEGATIVE	2	0.86	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M670		PATIENT		43	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	2	0	NEGATIVE		1.06	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M671		PATIENT		30	CAUCASIAN	POSITIVE	RD	POSITIVE	T1	N1	3	90	NEGATIVE		1.07	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M673		PATIENT		58	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N3	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M675		PATIENT		64	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N1	2	1	NEGATIVE	1		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M679		PATIENT		72	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N0	3	0	NEGATIVE	2	1.42	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M681		PATIENT		33	HISPANIC	NEGATIVE	RD	NEGATIVE	T3	N0	3	0	NEGATIVE	2	1.27	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M682		PATIENT		50	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2		NEGATIVE	2	1.2	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M683		PATIENT		59	CAUCASIAN	NEGATIVE	RD	POSITIVE	T2	N0	3	5	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M685		PATIENT		53	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	1	90	NEGATIVE		0	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M690		PATIENT		73	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	1	95	NEGATIVE	1	0.86	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M692		PATIENT		46	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T2	N3	2	0	NEGATIVE	1		1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M693		PATIENT		47	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	NEGATIVE		0.82	1||2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M695		PATIENT		43	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	3	80	NEGATIVE		1.21	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M713		PATIENT		50	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T1	N1	3	0	NEGATIVE		1.1	1	5-fluorouracil||Epirubicin||Cyclophosphamide
ML20		PATIENT		48	AFRICAN-AMERICAN	POSITIVE	PCR	POSITIVE	T4	N1	3		NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU01		PATIENT		73	HISPANIC	POSITIVE	RD	NEGATIVE	T4	N1	2	100	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU07		PATIENT		71	HISPANIC	POSITIVE	RD	NEGATIVE	T4	N1	3	30	NEGATIVE	1		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU08		PATIENT		40	HISPANIC	NEGATIVE	RD	NEGATIVE	T3	N1		0	NEGATIVE	0		1	5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU09		PATIENT		47	HISPANIC	POSITIVE	RD	POSITIVE	T4	N1	2	50	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU11		PATIENT		50	HISPANIC	NEGATIVE	RD	NEGATIVE	T4	N1	2	0	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU12-14		PATIENT		65	HISPANIC	POSITIVE	RD	POSITIVE	T2	N2	3	95	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU14-16		PATIENT		58	HISPANIC	NEGATIVE	RD	NEGATIVE	T4	N2	3	0	NEGATIVE			1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU53		PATIENT		35	HISPANIC	NEGATIVE	RD	NEGATIVE	T3	N1		0	NEGATIVE	0		1	5-fluorouracil||Doxorubicin||Cyclophosphamide
PERU55		PATIENT		42	HISPANIC	NEGATIVE	RD	NEGATIVE	T4	N1		0	NEGATIVE	0		1	5-fluorouracil||Doxorubicin||Cyclophosphamide
US002		PATIENT		36		NEGATIVE	RD	NEGATIVE	T3	N2	3		NEGATIVE	1	1.5	1	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US031		PATIENT		50		NEGATIVE	RD	NEGATIVE	T3	N1	3		POSITIVE		3	1	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US092		PATIENT		61		POSITIVE	RD	POSITIVE	T3	N0			NEGATIVE		1.5	2	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US097		PATIENT		46		POSITIVE	RD	POSITIVE	T3	N0			NEGATIVE	0	1.3	2	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US120		PATIENT		52		NEGATIVE	RD	NEGATIVE		N2			POSITIVE	2		1	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US123		PATIENT				NEGATIVE	RD	NEGATIVE		N			NEGATIVE				
US125		PATIENT		41		NEGATIVE	RD	NEGATIVE	T3	N2			NEGATIVE	0		1	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US129		PATIENT		64		NEGATIVE	PCR	NEGATIVE	T3	N1			NEGATIVE	0		1	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US134		PATIENT		46		POSITIVE	RD	POSITIVE	T3	N0			POSITIVE		3	1	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
US147		PATIENT		46		NEGATIVE	RD	NEGATIVE	T3	N1			NEGATIVE	2	1.5	1	Taxol||Xeloda||5-fluorouracil||Doxorubicin||Cyclophosphamide
M696		PATIENT		53	AFRICAN-AMERICAN	NEGATIVE	PCR	NEGATIVE	T2	N1	3	0	NEGATIVE	2	0.98	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M709		PATIENT		51	CAUCASIAN	NEGATIVE	PCR	NEGATIVE	T4	N2	3		NEGATIVE		1.9	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M710		PATIENT		53	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	100	NEGATIVE	0		2||1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M714		PATIENT		64	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	3	30	NEGATIVE		0.96	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M717		PATIENT		52	ASIAN	POSITIVE	RD	POSITIVE	T2	N0	1	100	NEGATIVE		0.94	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M718		PATIENT		36	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N0	3	0	NEGATIVE	2	1.32	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M723		PATIENT		63	HISPANIC	POSITIVE	RD	POSITIVE	T2	N1	2	95	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M725		PATIENT		46	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N3	1	91	NEGATIVE	1	1.25	1	5-fluorouracil||Epirubicin||Cyclophosphamide||Taxol
M728		PATIENT		49	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T3	N1	3	100	NEGATIVE	0		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M732		PATIENT		50	CAUCASIAN	NEGATIVE	RD	NEGATIVE	T2	N2	3	0	NEGATIVE	0		1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M734		PATIENT		36	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T2	N0	2	90	NEGATIVE		1.18	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M744		PATIENT		44	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	95	NEGATIVE		0.87	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M746		PATIENT		56	AFRICAN-AMERICAN	POSITIVE	RD	POSITIVE	T3	N0	1	10	NEGATIVE	0		2	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M753		PATIENT		49	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N0	2	100	NEGATIVE		1.18	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M765		PATIENT		62	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N1	3	95	NEGATIVE		0.93	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M767		PATIENT		51	CAUCASIAN	POSITIVE	PCR	POSITIVE	T2	N0	2	91	NEGATIVE	1		1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M774		PATIENT		49	CAUCASIAN	POSITIVE	RD	POSITIVE	T2	N1	2	95	NEGATIVE	1	0.83	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M781		PATIENT		40	CAUCASIAN	POSITIVE	RD	POSITIVE	T3	N0	2	90	NEGATIVE	0	1.17	1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M782		PATIENT		53	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N3	1	90	NEGATIVE	0	0.54	2	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M784		PATIENT		58	CAUCASIAN	POSITIVE	RD	POSITIVE	T4	N0	3	100	NEGATIVE		1.29	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M795		PATIENT		64	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N0	2	85	NEGATIVE		0.86	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide
M801		PATIENT		45	CAUCASIAN	POSITIVE	RD	NEGATIVE	T2	N1	2	91	NEGATIVE	1		1	Taxol||5-fluorouracil||Epirubicin||Cyclophosphamide
M806		PATIENT		49	HISPANIC	POSITIVE	RD	POSITIVE	T4	N2	3	100	NEGATIVE	1	1.16	1	Taxol||5-fluorouracil||Doxorubicin||Cyclophosphamide